Schiff bases of sulphonamides as a new class of antifungal agent against multidrug-resistant *Candida auris*

Asad Hamad\(^1,2\) | Yiyuan Chen\(^2\) | Mohsin A. Khan\(^1\) | Shirin Jamshidi\(^2\) | Naima Saeed\(^2\) | Melanie Clifford\(^3\) | Charlotte Hind\(^3\) | J. Mark Sutton\(^3\) | Khondaker Miraz Rahman\(^2\)

1Department of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan
2Institute of Pharmaceutical Science, King’s College London, London, UK
3Public Health England, National Infections Service, Salisbury, UK

**Correspondence**
Khondaker Miraz Rahman, Institute of Pharmaceutical Science, King’s College London, London SE1 9NH, UK.
Email: k.miraz.rahman@kcl.ac.uk

**Funding information**
PHE, Grant/Award Number: 109502, 109505 and 111742; King’s College London

**Abstract**
Invasive *Candida* infections in hospitalized and immunocompromised or critically ill patients have become an important cause of morbidity and mortality. There are increasing reports of multidrug resistance in several *Candida* species that cause Candidemia, including *C. glabrata* and *C. auris*, with limited numbers of antifungal agents available to treat patients with invasive *Candida* infections. Therefore, there is an urgent need to discover new antifungal agents that work against multidrug-resistant *Candida* species, particularly *C. auris*, which has been identified as an emerging global pathogen. In this article, we report a new class of antifungal agents, the Schiff bases of sulphonamides, that show activity against all *Candida* species tested, with an MIC range of 4–32 µg/ml. Compound 2b showed activity against *C. glabrata* and a panel of fluconazole-resistant *C. auris* strains, with MICs of 4–16 µg/ml. The drug-like nature of these Schiff bases offers opportunities to optimize these compounds with medicinal chemistry techniques to obtain more potent analogs that can be progressed toward pre-clinical evaluation.

**KEYWORDS**
antifungal resistance, *Candida auris*, candidemia, Schiff bases, sulphonamides

1 | INTRODUCTION

The need for better antifungal therapy is urgent due to the high mortality rates that are associated with invasive fungal diseases, the limited number of effective antifungal classes, their associated toxicity, and the growing number of infections caused by multidrug-resistant strains (Perlin et al., 2017). Coupled with a significant increase in the immunocompromised population, including those with HIV, cancer patients, and transplant recipients, this has led to a dramatic expansion of human invasive mycoses cases, particularly invasive candidiasis, which has become a global public health problem (Kullberg & Arendrup, 2015). A large number of resistant *Candida* species against first- and second-line antifungal therapeutics, fluconazole, and echinocandins, for instance, are being reported in the clinic (Sanguinetti et al., 2015; Whaley et al., 2017). According to a report from the CDC, 7% of the strains were found to be resistant against fluconazole among all the *Candida* species isolated from the circulatory system. (Magill et al., 2014). Of those, 70% were identified as *Candida glabrata* and *Candida krusei*, which are intrinsically associated with innate resistance to various azole drugs (Pfaller & Diekema, 2007; Whaley et al., 2017). There are very few treatment options for multidrug-resistant *Candida* infections as azoles and echinocandins remain the drug of choice despite their lack of efficacy as the remaining drugs have poor toxicity profiles and are often difficult to administer. (Arendrup & Patterson, 2017).
Candida auris is an emerging fungal pathogen that was firstly identified in Asia in 2009. According to data from the CDC, the case count was increased by 328% in 2018, and until August 2020, more than 1000 cases were reported (Bhattacharya et al., 2020). The major concerns for C. auris are its multidrug resistance, high mortality rate, difficulty in fast identification, and high risks of healthcare outbreaks (Nett, 2019). In 2020, several cases of hospital candidemia outbreaks related to COVID-19 in Intensive Care Units and severe fungal co-infections have been reported across the world including UK (White et al., 2020), India (Chowdhary et al., 2020), and China (Song et al., 2020). Treatment of candidiasis, including infections caused by C. auris, relies on very few classes of antifungal drugs. The vast majority of C. auris isolates sent to CDC possessed resistance to fluconazole and up to one third are resistant to amphotericin B (Borman et al., 2016). Therefore, there is an urgent need to identify new antifungal agents containing new chemical classes to treat drug-resistant Candida infections.

Sulphonamides are a versatile class of drug-like chemical scaffolds that have shown a wide range of therapeutic activities including antimicrobial (Seydel, 1968), antitumor (Bouissane et al., 2006), antiviral (Gawin et al., 2008), and anti-inflammatory (Weber et al., 2004) effects. More recently sulphonamide derivatives like phosphodiesterase-5 inhibitor sildenafil (Kim et al., 2001) are being used in the treatment of erectile dysfunction. In addition, a wide variety of sulphonamide derivatives have been evaluated as experimental agents against ulcerative colitis (Wilson et al., 2004), rheumatoid arthritis (Levin et al., 2002), obesity (Hu et al., 2001), anticancer agents (Ma et al., 2012), and in Alzheimer’s disease (Roush et al., 1998). One of the widely employed techniques to explore the therapeutic utility of this chemical class is the conversion of sulphonamides into Schiff bases by condensing them with different aldehyde derivatives. The Schiff bases have been reported as anti-infective agents including antimalarial (Rathelot et al., 1995), antimicrobial (Shi et al., 2007), antifungal (Guo et al., 2007), antiviral (Wang et al., 1990), anticonvulsant (Verma et al., 2004), and antiplasmodial (Adams et al., 2016) agents.

In this study, we explored the antifungal potential of three marketed sulfa drugs and their Schiff bases to identify new antifungal agents containing a sulphonamide chemical scaffold. While parent sulfa drugs were found to be inactive against all pathogenic Candida species tested, their Schiff bases showed promising antifungal activities against a panel of pathogenic Candida strains including an extended panel of multidrug-resistant C. auris.

2 | RESULTS AND DISCUSSION

The Schiff base derivatives of the sulfa drugs were synthesized by condensation of commercially available 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide (sulphamethoxazole), 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide (sulfamethazine), and 4-amino-N-(6-methoxypyridazin-3-yl)benzenesulfonamide (Sulfamethoxypyridazine) with appropriate substituted aromatic aldehydes (Figure 1). A range of solvents with varying polarity was used to optimize the reaction conditions, and finally, ethanol with few drops of acetic acid was used as the optimum solvent mixture for the condensation reactions (Scheme 1). In every case, an equimolar quantity of sulphonamides and substituted aromatic aldehydes were used and the overall yield of the reactions ranged from 35 to 92%. The compounds were purified either by recrystallization or by liquid column chromatography prior to characterization, and all compounds were at least 95% pure before they were considered
for microbiological evaluation. The structures of the synthesized Schiff bases were fully characterized with the help of $^1$H NMR, $^{13}$C NMR, and HRMS (ESI). Schiff bases of this type were previously reported by us (Hamad, Abbas Khan, et al., 2020; Hamad, Khan, et al., 2020), and the NMR data were compared with the literature, where applicable.

The synthesized compounds (Figure 2) were initially tested against a multi-species panel of Candida strains to assess their antifungal activity. The panel consisted of C. albicans NCPF3281 and NCPF3179, C. auris TDG1912, C. glabrata NCPF8018, C. krusei NCPF3876, C. tropicalis NCPF8760, and C. parapsilosis NCPF3209 (Table 1). The Schiff bases that were found to be active against the C. auris strain TDG1912 were further tested against a larger panel of multidrug-resistant C. auris strains (TDG2506, TDG2512, TDG1102, TDG2211, NCPF8984, NCPF8977, and NCPF8971) to confirm this activity (Table 2). All strains of the extended C. auris panel are clinical strains, except TDG2512 and TDG1912, which were environmental isolates but from hospital environments (Table S1). The panel represents three major clades (South Asian, East Asian, and South African) of C. auris.

All parent sulfa drugs (Figure 1a) were found to be completely inactive against the Candida strains with MIC values greater than 128 µg/ml. A Schiff base of sulfamethoxazole, 2a, generated using benzaldehyde as the unsubstituted aromatic aldehyde was also found to be inactive against all strains tested. Intriguingly, the introduction of hydroxy and chlorine substitution on the aromatic aldehyde resulted in a Schiff base 2b with antifungal activities against the Candida strains including the C. auris strain TDG1912 which is resistant to fluconazole (Table 1). The Schiff base 2b had an MIC of 16 µg/ml against TDG1912, comparable to other Candida strains, except the C. glabrata strain NCPF8018 against which it had an MIC of 4–8 µg/ml, comparable to the activity of fluconazole. The Schiff base analog of sulfamethoxypridazine, 2c, containing the same aromatic aldehyde was synthesized to assess the importance of ring C (i.e., hydroxy and chloro-substituted phenyl ring, Figure 1b) in conferring antifungal activity to the sulfa drugs. The Schiff base 2c was also found to be active against the Candida strains with MICs ranging from 16 to 128 µg/ml. However, it was less active against all strains tested compared to 2b, but more active than fluconazole against the C. auris strain TDG1912. This suggests the heteroaryl ring A also plays a role in antifungal activity in addition to ring C of these Schiff bases (Figure 1b).

To assess the effect of the electronegative halogen atom on the antifungal activity of the Schiff bases, compound 2d was synthesized in which the chlorine was substituted with more electronegative fluorine. Both compounds 2c and 2d were Schiff bases of sulfamethoxypridazine with the fluorine substitution in ring C in place of chlorine which allowed direct comparison of the activity
of these two compounds. The Schiff base 2d was slightly less active compared to 2c against all Candida strains (MIC range 16 to >128 µg/ml), and it was found to be inactive against the C. krusei NCPF3876 strain. This suggests that the introduction of the more electronegative fluorine in ring C has a negative impact on antifungal activity for this chemical scaffold.

To assess the importance of halogen substitution in ring C of the Schiff bases, compound 2e was synthesized in which the halogen atom in position-4 was replaced with another hydroxy substituent. Interestingly, the compound was found to be inactive against all Candida strains (Table 1) suggesting the presence of the halogen atom in the ring is essential for antifungal activity. The Schiff base 2f was synthesized to determine the effect of multiple halogen substitutions on activity. In this compound, the hydroxy group in position-2 was replaced with a chlorine substituent allowing a direct comparison between 2d and 2f. Surprisingly, compound 2f was also found to be completely inactive against all Candida strains, indicating the importance of the hydroxy group at position-2 of the C-ring.

Next, we evaluated the effect of the position of the halogen substitution on the activity of the Schiff bases. In compounds 2b, 2c, and 2d, the 2-position was substituted with a hydroxy group and the 4-position was substituted with a halogen atom. Two Schiff bases 2g and 2h were synthesized with halogen substitutions on position-5 of the ring while the hydroxy group was kept at position-2. Both compounds 2g and 2h were active against all Candida strains with activity comparable to 2b and 2c. This suggests the position of the halogen substituent on the ring has a minor influence on the antifungal activity of the compounds.

After observing promising activity against the multi-species Candida panel, we decided to focus more specifically on the ability of these Schiff bases to kill multidrug-resistant C. auris strains. The Schiff bases 2b-2e were tested against an extended panel of fluconazole-resistant C. auris strains. All Schiff bases were found to be active against the extended C. auris panel, with MICs ranging from 8 to 128 µg/ml (Table 2). The activity pattern of the compounds somewhat mirrored their activities against the multi-species Candida panel with 2b emerging as the most active compound with MICs in the range of 8–128 µg/ml. 2d was least active with an MIC range of 32–128 µg/ml. Interestingly, the Schiff base 2h with the halogen (bromine) substitution at the C5-position was found to be more active compared to 2g, and its activity against the C. auris panel was comparable to that observed for compound 2b. Overall, the activity of these Schiff bases against the C. auris panel is encouraging and provides a new chemical scaffold to develop more potent antifungal agents against a pathogen of global concern. This is the first report

| TABLE 1 Antifungal activity of the Schiff bases against a multi-species Candida panel |
|---------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
|                                | Fluconazole | 2a  | 2b  | 2c  | 2d  | 2e  | 2f  | 2g  | 2h  |
| C. auris TDG1912               | >128        | 16  | 32  | 64–128 | >128 | >128 | 32  | 32  |
| C. albicans NCPF3281           | 0.12 – 0.25 | >128 | 16  | 32  | 32–64 | >128 | >128 | 32  | 32–64 |
| C. albicans NCPF 3179          | 0.5         | >128 | 16–32 | 32–64 | 64  | >128 | >128 | 64  | 64–128 |
| C. glabrata NCPF8018           | 2           | >128 | 4–8  | 16  | 16–32 | >128 | >128 | 8–16| 16  |
| C. krusei NCPF3876             | 16–32       | >128 | 32–64 | 128 | >128 | >128 | 64  | 64–128 |
| C. tropicalis NCPF8760         | 8           | >128 | 32  | 64  | 64–128 | >128 | >128 | 64  | 64  |
| C. parapsilosis NCPF3209       | 0.12–0.25   | >128 | 32–64 | >128 | >128 | >128 | 64  | 64–128 |

Note: MIC in µg/ml.

| TABLE 2 Antifungal activity of selected Schiff bases against the extended C. auris panel |
|---------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|
|                                | 50% MIC | Fluconazole | 2b  | 2c  | 2d  | 2g  | 2h  |
| C. auris TDG2512               | 16      | 16           | 32–64 | 128  | 64  | 16  |
| C. auris TDG1102               | 128     | 16–32        | 32   | 64–128 | 64  | 16–32 |
| C. auris TDG2211               | 128     | 16–32        | 32–64 | 128  | 64–128 | 16–32 |
| C. auris TDG2506               | >128    | 16           | 32   | 32–64 | 32–64 | 16  |
| C. auris NCPF8984              | >128    | 16           | 32   | 64–128 | 32–64 | 16  |
| C. auris NCPF8971              | 32      | 8–16         | 32   | 64  | 64  | 8–16 |
| C. auris NCPF8977              | 32      | 16           | 32–64 | 64–128 | 64  | 16  |

Note: MIC in µg/ml.
of the sulfonamide class of antifungal agents with activity against C. auris.

The selectivity and therapeutic utility of these Schiff bases were further assessed using an MTT cytotoxicity assay against a non-tumor lung fibroblast cell line WI38. The Schiff bases were tested at 40 and 80 µg/ml concentrations and were found to be non-toxic (ESI) against this cell line at both concentrations tested (viability >90% at experimental conditions) suggesting a good selectivity for fungal pathogens.

The mechanism of antifungal activities of these Schiff bases is not known. A molecular modeling study with the wild-type and mutant Erg11 (F126L, F132Y, and K143R), the target enzyme for azole antifungals, showed the Schiff bases were capable of binding near theazole binding pocket of both the wild-type and mutant Erg11 from C. auris. The molecular modeling study was conducted for compounds 2b, 2c, and 2h, and all three ligands were able to bind to the azole binding pocket (Figure 3 and Figures S10-S14) while the parent sulfa drugs did not interact with the Erg11. This suggests inhibition of Erg11 as a potential mechanism of action of these Schiff bases. However, more studies are required to determine the molecular mechanism of action of these Schiff bases against C. auris, which might initiate future drug discovery efforts using the Schiff bases of sulfonamides as a new antifungal chemical scaffold.

3 | CONCLUSION

A new sulfonamide-based chemical scaffold has been identified with broad-spectrum antifungal activity against major Candida species, including multidrug-resistant C. auris strains. The Schiff bases are non-toxic against healthy human cell lines at the concentrations tested, which offers excellent opportunities to develop more potent analogs of this chemical class as antifungal agents. It was possible to establish a limited structure-activity relationship that shows the importance of both halogen and hydroxy substituents on antifungal activity. Molecular modeling suggests Erg11 inhibition as a potential mechanism of action, but further work is necessary to determine the target and mechanism of this chemical class.

4 | MATERIALS AND METHODS

4.1 | General Experimental

All the solvents and reagents were commercially available from Sigma-Aldrich, Fluorochem, Alfa Aesar, and Fisher Scientific, and were used directly without further purification. Melting points were measured with the Gallenkamp melting point apparatus. $^1$H and $^{13}$C nuclear magnetic resonance (NMR) spectra were obtained by a 400 MHz Bruker Spectrospin which was fitted with a Bruker SampleXpress autosampler system, and Topspin 7.1 was used for NMR spectra analysis. Chemical shifts of all compounds were calibrated with tetramethylsilane (TMS at $\delta = 0$), with splittings outlined as singlet (s), doublet (d), and triplet (t). Fourier-transform infrared (FTIR) spectroscopy was performed on Bruker Tensor 27 FTIR spectrophotometer with the sample prepared using the KBr pellet press method. High-resolution mass spectroscopy (HRMS) was performed using Agilent HP6890 GC with HP 7683 Injector interfaced directly to Agilent HP 5973 MSD (EI) instrument.

4.2 | Chemistry

4.2.1 | General procedure for the synthesis of Schiff bases of 4-aminobenzenesulfonamides

Sulphonamide, aromatic aldehyde, and glacial acetic acid were added to the absolute ethanol in a round-bottomed flask, and the mixture was heated under reflux for 3 h, before cooling down to room temperature upon completion. The crude product was obtained by filtration, after which recrystallization was carried out for further purification. The product was dried overnight in the VacuumTherm (Thermo Scientific) vacuum oven prior to characterization. All final products were determined using mass spectroscopy and NMR.

FIGURE 3 The Schiff 2b occupies the azole binding pocket of wild-type Erg11. (a) 3D molecular model showing fluconazole at the azole binding pocket and (b) 3D molecular model showing 2b at the azole binding pocket
4-(benzylideneamino)-N-(5-methylisoxazol-3-yl) benzenesulphonamide (2a)

Physical appearance: Reddish Orange crystals; Reaction yield (80%); m. p. 197–199 °C; Mol. Wt. 341.38; 1H NMR (DMSO-d₆), δ ppm; 8.62 (s, 1H), 7.88 (d, 2H, J = 8.23 Hz), 7.76 (d, 2H, J = 7.78 Hz), 7.59 (t, 1H, J = 8.07 Hz), 7.56 (dd, 2H, J = 8.08 Hz, J = 2.02 Hz), 7.43 (d, 2H, J = 8.13 Hz), 6.05 (s, 1H), 3.23 (s, 1H, NH), 2.27 (s, 3H); 13C NMR (DMSO-d₆), δ ppm; 139.23, 129.10, 122.34, 153.31, 149.34, 95.96, 169.77, 12.53, 159.47, 121.98, 127.43, 132.22; HRMS (ESI-MS, m/z): calculated for [C₁₇H₁₇N₂O₅S + H]⁺: 401.0905 found [M⁺H]⁺ 401.0914.

4-([2-chloro-4-fluorophenyl]methylidene)amino)-N-(6-methoxy-2-pyridazin-3-yl)benzene-1-sulphonamide (2f)

Physical appearance: Reddish orange crystals; Reaction yield (87%); m. p. 223–225°C; Mol. Wt. 420.85; 1H NMR (DMSO-d₆), δ ppm; 8.80 (s, 1H), 7.88 (d, 2H, J = 6.95 Hz), 7.65 (d, 1H, J = 8.21 Hz), 7.38 (d, 2H, J = 8.17 Hz), 7.74 (d, 1H, J = 7.98 Hz), 6.85 (s, 1H), 6.57 (d, 1H, J = 7.29 Hz), 6.55 (d, 1H, J = 8.18 Hz), 3.87 (s, 1H), 3.84 (s, 3H); 13C NMR (DMSO-d₆), δ ppm; 136.36, 128.00, 121.92, 154.33, 151.23, 120.23, 121.62, 159.91, 54.80, 158.75, 129.62, 136.91, 117.78, 165.52, 112.97, 133.36; HRMS (ESI, m/z): calculated for [C₁₈H₁₄FClN₄O₃S + H]⁺: 421.0520 found [M⁺H]⁺ 421.0532.

Determination of minimum inhibitory concentration

The MIC was determined according to modified EUCAST guidelines for azoles, echinocandins, and flucytosine in which we culture the test organisms overnights in liquid rather than on agar for MIC testing and adjust to the correct cell concentration using absorbance. Briefly, strains were grown overnight in RPMI-1640-MOPS containing 2% glucose and back-diluted to a concentration...
of 0.5–5 × 10⁵ mCFU/ml. The back-diluted cultures were added to a doubling dilution series of compounds (concentrations ranging from 128 µg/ml to 0.125 µg/ml) in non-binding polystyrene 96-well plates and incubated at 37°C for 24 h. Wells were mixed by gentle pipetting, and then, MICs were defined as the lowest concentration of compound resulting in ≥50% growth inhibition compared to untreated drug-free solvent controls.

### 4.4 | Cell culture and MTT assay

The non-tumor WI38 cell line was obtained from the American Type Culture Collection. The cells were maintained in a humidified atmosphere in an incubator at 37°C containing 5% CO₂. The cell line was maintained in Dulbecco’s Modified Eagles Media (DMEM; Invitrogen) which was supplemented with fetal bovine serum (10% v/v; Invitrogen). The cells were plated in a 96-well plate for the MTT viability assay, and the cells were incubated with the Schiff bases 2a-2h for 24 h. The MTT reagent was added to each well after the removal of media using an aspirator, and the formazan crystals were dissolved in DMSO. The absorbance values were read using an Envision plate reader (PerkinElmer). The values were normalized with the blank, and the normalized values were used for the determination of the % of viability. Each experiment was performed 6 times, and the result is reported as average values.

### 4.5 | Molecular modeling

The 3D structures of wild type and F126L, F132Y, and K143R mutant ERG11 were obtained from homology modeling using the retrieved amino acid sequence from gene sequence with the code of A0A2H4Q4C0 (Template PDB id code: 5v5z, Seq. identity: 71.46%). Three forms of the mutations were generated using the PyMol program with an appropriate rotamer of mutated amino acid, which does not lead to any steric clash with the neighboring residues. All the structures were minimized and equilibrated using the AMBER program. Then molecular docking was performed by GOLD software by applying ChemScore as the scoring function. The cavity definition for the target protein was performed based on the known binding site of the corresponding crystal structures applied in this study.

### ACKNOWLEDGMENTS

We thank HEC Pakistan for supporting AH’s doctoral placement at King’s College London. We acknowledge funding from PHE Pipeline (project 109502) and grant-in-aid projects (Project 109505 and 111742) for this work. We also thank Ginny Moore of Public Health England for providing C. auris strains isolated from UK hospitals.

### CONFLICT OF INTEREST

None declared.

### AUTHOR CONTRIBUTIONS

Asad Hamad: Formal analysis (supporting); Investigation (lead); Writing-review & editing (supporting). Yiyuan Chen: Formal analysis (supporting); Investigation (supporting); Methodology (supporting); Project administration (supporting); Writing-original draft (supporting). Mohsin A. Khan: Conceptualization (supporting); Funding acquisition (supporting); Methodology (supporting); Project administration (supporting); Supervision (supporting). Shirin Jamshidi: Investigation (supporting); Methodology (supporting); Writing-review & editing (supporting). Naima Saeed: Formal analysis (supporting); Investigation (supporting); Writing-review & editing (supporting). Charlotte Hind: Formal analysis (equal); Investigation (equal); Writing-review & editing (supporting). J. Mark Sutton: Conceptualization (supporting); Funding acquisition (equal); Project administration (equal); Supervision (equal); Writing-review & editing (supporting). Khondaker Miraz Rahman: Conceptualization (lead); Funding acquisition (equal); Project administration (lead); Supervision (lead); Writing-original draft (lead); Writing-review & editing (lead).

### ETHICS STATEMENT

None required.

### DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are included in this published article and its supplementary material.

### ORCID

J. Mark Sutton [https://orcid.org/0000-0002-2288-0446](https://orcid.org/0000-0002-2288-0446)

Khondaker Miraz Rahman [https://orcid.org/0000-0001-8566-8648](https://orcid.org/0000-0001-8566-8648)

### REFERENCES

Adams, M., Barnard, L., de Kock, C., Smith, P. J., Wiesner, L., Chibale, K., & Smith, G. S. (2016). Cyclopalladated organosilane–tethered thiosemicarbazones: Novel strategies for improving antiplasmodial activity. Dalton Transactions, 45(13), 5514–5520. [https://doi.org/10.1039/C5DT04918K](https://doi.org/10.1039/C5DT04918K).

Arendrup, M. C., & Patterson, T. F. (2017). Multidrug-resistant Candida: Epidemiology, molecular mechanisms, and treatment. The Journal of Infectious Diseases, 216(suppl_3), S445–S451. [https://doi.org/10.1093/infdis/jix131](https://doi.org/10.1093/infdis/jix131).

Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020). Candidiasis and mechanisms of antifungal resistance. *Antibiotics*, 9(6), 312. [https://doi.org/10.3390/antibiotics9060312](https://doi.org/10.3390/antibiotics9060312).

Borman, A. M., Szekely, A., & Johnson, E. M. (2016). Comparative pathogenicity of United Kingdom isolates of the emerging pathogen *Candida auris* and other key pathogenic Candida species. *MSphere*, 1(4), e00189–16.

Bouissane, L., El Kazzouli, S., Léonce, S., Pfeiffer, B., Rakib, E., Khouli, M., & Guillaumet, G. (2006). Synthesis and biological evaluation of N-(7-indazolyl)benzenesulfonamide derivatives as potent cell cycle inhibitors. *Bioorganic & Medicinal Chemistry*, 14(4), 1078–1088. [https://doi.org/10.1016/j.bmc.2005.09.037](https://doi.org/10.1016/j.bmc.2005.09.037).

Chowdhary, A., Tarai, B., Singh, A., & Sharma, A. (2020). Multidrug-resistant *Candida auris* infections in critically Ill coronavirus disease...
patients, India, April–July 2020. Emerging Infectious Diseases, 26(11), 2694.

Gawin, R., De Clercq, E., Naesens, L., & Kosztyikowska-Stawinska, M. (2008). Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure. Bioorganic & Medicinal Chemistry, 16(18), 8379–8389. https://doi.org/10.1016/j.bmc.2008.08.041.

Hu, B., Ellingboe, J., Han, S., Largis, E., Lim, K., Malamas, M., Mulvey, R., Niu, C., Oliphant, A., Pelletier, J., Singanallatore, T., Sum, F.-W., Tillet, J., & Wong, V. (2001). Novel (4-piperidin-1-yl)-phenyl sulfonylamides as potent and selective human β3 agonists. Bioorganic & Medicinal Chemistry, 10(4), 1329–1332. https://doi.org/10.1016/S0968-0896(01)00114-6.

Kim, D.-K., Lee, J. Y., Lee, N., Ryu, D. H., Kim, J.-S., Lee, S., Choi, J.-Y., Ryu, J.-H., Kim, N.-H., Im, G.-J., Choi, W.-S., & Kim, T.-K. (2001). Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring. Bioorganic & Medicinal Chemistry, 9(11), 3013–3021. https://doi.org/10.1016/S0968-0896(01)00200-0.

Kullberg, B. J., & Anderegg, M. C. (2015). Invasive candidiasis. New England Journal of Medicine, 373(15), 1445–1456. https://doi.org/10.1056/NEJMra1315399.

Levin, J., Chen, J., Du, M., Nelson, F., Killar, L., Skala, S., & Barone, D. (2002). Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group. Bioorganic & Medicinal Chemistry Letters, 12(8), 1199–1202.

Ma, T., Fuld, A. D., Rigas, J. R., Hague, A. E., Gordon, G. B., Dmitrovsky, E., & Dragnev, K. H. (2012). A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. Chemotherapy, 58(4), 321–329. https://doi.org/10.1159/000343165.

Nett, J. E. (2019). Candida auris: An emerging pathogen “incognito”? PLoS Path., 15(4), e1007638. https://doi.org/10.1371/journal.ppat.1007638.

Nicholls, A. J., & Nicholls, D. (2019). The global problem of antifungal resistance: Prevalence, mechanisms, and management. The Lancet Infectious Diseases, 19(12), e383–e392. https://doi.org/10.1016/S1473-3099(19)30316-X.

Pfaller, M. A., & Diekema, D. J. (2007). Epidemiology of invasive candidiasis: A persistent public health problem. Clinical Microbiology Reviews, 20(1), 133–163. https://doi.org/10.1128/CMR.00029-06.

Rathelot, P., Vanelle, P., Gasquet, M., Delmas, F., Crozet, M., Timon-David, P., & Maldonado, J. (1995). Synthesis of novel functionalized 5-nitroisooquinolines and evaluation of in vitro antimalarial activity. European Journal of Medicinal Chemistry, 30(6), 503–508. https://doi.org/10.1016/0223-5234(96)88261-4.

Roush, W. R., Gwaltney, S. L., Cheng, J., Scheidt, K. A., McKerrow, J. H., & Hansell, E. (1998). Vinyl sulfonate esters and vinyl sulfonamides: Potent, irreversible inhibitors of cysteine proteases. Journal of the American Chemical Society, 120(42), 10994–10995.

Sanguinetti, M., Posteraro, B., & Lass-Flörl, C. (2015). Antifungal drug resistance among Candida species: Mechanisms and clinical impact. Mycoses, 58, 2–13.

Seydel, J. K. (1968). Sulfonamides, structure-activity relationship, and mode of action: Structural problems of the antibacterial action of 4-aminobenzoic acid (PABA) antagonists. Journal of Pharmaceutical Sciences, 57(9), 1455–1478. https://doi.org/10.1021/jp2600570902.

Shi, L., Ge, H.-M., Tan, S.-H., Li, H.-Q., Song, Y.-C., Zhu, H.-L., & Tan, R.-X. (2007). Synthesis and antimicrobial activities of Schiff bases derived from 5-chlorosalicylaldehyde. European Journal of Medicinal Chemistry, 42(4), 558–564. https://doi.org/10.1016/j.ejmech.2006.11.010.

Song, G., Liang, G., & Liu, W. (2020). Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China. Mycopathologia, 185(4), 599–606.

Verma, M., Pandeya, S. N., Singh, K. N., & Stables, J. P. (2004). Anticonvulsant activity of Schiff bases of isatin derivatives. Acta Pharmacologica, 54(1), 49–56.

Wang, P. H., Keck, J. G., Lien, E. J., & Lai, M. M. (1990). Design, synthesis, testing, and quantitative structure-activity relationship analysis of substituted salicylaldehyde Schiff bases of 1-amino-3-hydroxyguanidine tosylate as new antiviral agents against coronavirus. Journal of Medicinal Chemistry, 33(2), 608–614. https://doi.org/10.1021/jm00164a023.

Weber, A., Casini, A., Heine, A., Kuhn, D., Supuran, C. T., Scozzafava, A., & Klebe, G. (2004). Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: New pharmacological opportunities due to related binding site recognition. Journal of Medicinal Chemistry, 47(3), 550–557.

Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017). Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Frontiers in Microbiology, 7, 2173. https://doi.org/10.3389/fmicb.2016.02173.

White, P. L., Dhillon, R., Hughes, H., Wise, M. P., & Backx, M. (2020). COVID-19 and fungal infection: The need for a strategic approach. The Lancet Microbe, 1(5), e196. https://doi.org/10.1016/s2666-5247(20)30127-0.

Wilson, C. O., Gisvold, O., Block, J. H., & Beale, J. M. (2004). Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry. In J. H. Block, & J. M. Beale Jr (Eds.), Lippincott Williams & Wilkins.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.